(-0.06%) 5 475.25 points
(-0.10%) 38 778 points
(-0.02%) 19 917 points
(0.22%) $80.51
(1.33%) $2.83
(0.23%) $2 334.40
(-0.16%) $29.35
(-0.18%) $969.20
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases...
Stats | |
---|---|
Šios dienos apimtis | 825 030 |
Vidutinė apimtis | 1.17M |
Rinkos kapitalizacija | 7.56B |
EPS | $-0.730 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-0.610 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-15.19 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0120 (0.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-05 | Gordon Christopher R | Buy | 10 461 | Common Stock |
2024-06-05 | Koppel Adam | Buy | 10 461 | Common Stock |
2024-06-05 | Coles N Anthony | Buy | 10 290 | Common Stock |
2024-06-05 | Dekkers Marijn E | Buy | 10 461 | Common Stock |
2024-06-05 | Patrick Deval L | Buy | 10 461 | Common Stock |
INSIDER POWER |
---|
9.21 |
Last 99 transactions |
Buy: 1 749 628 | Sell: 1 442 502 |
Tūris Koreliacija
Cerevel Therapeutics Koreliacija
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cerevel Therapeutics Koreliacija - Valiuta/Žaliavos
Cerevel Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-4.90M (0.00 %) |
EPS: | $-2.32 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.650 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.